Denny Lanfear, Coherus BioSciences CEO
June 16, 2023 07:34 AM EDTUpdated 08:48 AM
People
Deals

Co­herus to buy Sur­face On­col­o­gy in stock deal val­ued at $65M

Kyle LaHucik

Senior Reporter

Co­herus Bio­Sciences is mak­ing a small stock-for-stock trans­ac­tion to shore up its im­muno-on­col­o­gy pipeline in an ac­qui­si­tion of Sur­face On­col­o­gy that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times